Alla Stavnitser, BS

Generic atorvastatin led to an increase in generic dispensing rate and a reduction in the cost of treatment for patients requiring cholesterol-lowering treatment. The upcoming introduction of the PCSK9 inhibitor may change this trend.

Multiple sclerosis (MS) is of interest because it is one of the most costly neurological diseases and the introduction of the first oral treatments in 2010 amplified high treatment costs of MS even further.